Copyright
©The Author(s) 2004.
World J Gastroenterol. Mar 15, 2004; 10(6): 894-898
Published online Mar 15, 2004. doi: 10.3748/wjg.v10.i6.894
Published online Mar 15, 2004. doi: 10.3748/wjg.v10.i6.894
Table 3 Rate of change in the valuables between AMA-reduced group and AMA-unchanged group
| Factors | AMA-reduced group | AMA-unchanged group | t-test |
| ALT (IU/L) | 61.6 ± 124.81 | 52.0 ± 109.2 | 0.905 |
| ALP (IU/L) | -33.4 ± 24.8 | -33.8 ± 16.0 | 0.978 |
| γ-GTP (IU/L) | -2.8 ± 73.4 | -5.3 ± 39.8 | 0.950 |
| IgM (mg/dL) | -35.4 ± 0.6 | -7.1 ± 11.8 | 0.010 |
| Apo A-II (mg/dL) | 52.0 ± 17.3 | 37.4 ± 38.6 | 0.573 |
| Apo C-II (mg/dL) | 29.5 ± 13.8 | 10.6 ± 10.1 | 0.089 |
- Citation: Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol 2004; 10(6): 894-898
- URL: https://www.wjgnet.com/1007-9327/full/v10/i6/894.htm
- DOI: https://dx.doi.org/10.3748/wjg.v10.i6.894